← Leaderboards
Juan Lama
University Of California San Diego
$6,738,278
Attributed
$6,738,278
Total exposure
7
Grants
6
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1.2M · FY2005–17$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
Funding mix
By agency
NIH$6,738,278 · 7
By mechanism
R44$2,999,994 · 1
R43$1,981,437 · 4
R01$1,122,848 · 1
R21$633,999 · 1
Top collaborators
No co-investigators on record.
Most similar at University Of California San Diego
Same institution · by research overlap
- Ethan Bier$17,954,490
- Dirk-Uwe G Bartsch$8,281,467
- Richard Syd Kornbluth$3,601,719
- William Fenical$13,401,375
- Paul Taylor Martin$14,130,927
Others in their field
Top investigators on “Hiv Infections”
- Wafaa M. El-Sadr · Columbia University Health Sciences$965,259,079
- Lawrence Corey · Fred Hutchinson Cancer Center$728,701,834
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$467,263,656
- Judith S. Currier · University Of California Los Angeles$466,447,923
- Richard Marlink · Elizabeth Glaser Pediatric Aids Fdn$457,210,249
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$398,445,678
Research focus
Hiv InfectionsHelper T LymphocyteImmunomodulatorsCd4 MoleculeSpecificityProgramsTherapeutic IndexPre-ClinicalBasePrincipal InvestigatorSmall MoleculeInfectionAdverse EffectsPharmaceutical PreparationsVirusLeadInhibitor/AntagonistCellsSuccessProteinsFamilyResistancePharmaceutical ChemistryOral
Grant awards (21)
An immune-based approach for HIV eradication$665,610
R44 · FY2017 · AI · contact PI
An immune-based approach for HIV eradication$1,226,363
R44 · FY2016 · AI · contact PI
An immune-based approach for HIV eradication$1,108,021
R44 · FY2015 · AI · contact PI
Novel Screen to Identify Arenavirus Inhibitors$300,000
R43 · FY2014 · AI · contact PI
Novel Screen to Identify Arenavirus Inhibitors$299,739
R43 · FY2013 · AI · contact PI
Inhibitors of HIV-induced downregulation of HLA class I$210,169
R43 · FY2013 · AI · contact PI
Inhibitors of HIV-induced downregulation of HLA class I$300,000
R43 · FY2012 · AI · contact PI
Small-molecule inhibitors of HIV-induced receptor downmodulation$356,280
R43 · FY2010 · AI · contact PI
Small-molecule inhibitors of HIV-induced receptor downmodulation$296,875
R43 · FY2009 · AI · contact PI
Targeting HIV-1 Envelope glycoprotein incorporation$218,374
R43 · FY2009 · AI · contact PI
Fusion assay of the HIV-induced CD4 down-modulation$323,049
R21 · FY2006 · AI · contact PI
Fusion assay of the HIV-induced CD4 down-modulation$310,950
R21 · FY2005 · AI
ROLE OF CD4 DOWNMODULATION DURING HIV INFECTION$182,400
R01 · FY2004 · DA
ROLE OF CD4 DOWNMODULATION DURING HIV INFECTION$39,751
R01 · FY2004 · DA
ROLE OF CD4 DOWNMODULATION DURING HIV INFECTION$241,033
R01 · FY2003 · DA
ROLE OF CD4 DOWNMODULATION DURING HIV INFECTION$7,992
R01 · FY2003 · DA
ROLE OF CD4 DOWNMODULATION DURING HIV INFECTION$209,397
R01 · FY2002 · DA
ROLE OF CD4 DOWNMODULATION DURING HIV INFECTION$26,296
R01 · FY2002 · DA
ROLE OF CD4 DOWNMODULATION DURING HIV INFECTION$16,175
R01 · FY2002 · DA
ROLE OF CD4 DOWNMODULATION DURING HIV INFECTION$203,075
R01 · FY2001 · DA
ROLE OF CD4 DOWNMODULATION DURING HIV INFECTION$196,729
R01 · FY2000 · DA